SS-31 (Elamipretide) Research Guide: Mechanism, Studies & Mitochondrial Benefits
Shop Our Top Compounds
SS-31 (Elamipretide) Research Guide: Mechanism, Studies & Mitochondrial Benefits
All compounds discussed in this article are for research purposes only and are not for human consumption.
Introduction
Mitochondrial dysfunction is now recognized as a central driver of aging, cardiovascular disease, neurodegeneration, kidney injury, and a growing number of metabolic disorders. As the primary producers of adenosine triphosphate (ATP), mitochondria sustain virtually every energy-dependent process in the body β and when their function deteriorates, the consequences cascade across organs and tissues. This recognition has sparked intense scientific interest in compounds capable of directly targeting and restoring mitochondrial health.
Among the most extensively studied mitochondria-targeted therapeutics is SS-31, a synthetic tetrapeptide also known as Elamipretide, Bendavia, and MTP-131. Unlike conventional antioxidants that operate in the cytoplasm, SS-31 concentrates selectively within the inner mitochondrial membrane, where it binds the phospholipid cardiolipin to stabilize cristae architecture, enhance electron transport chain (ETC) efficiency, boost ATP synthesis, and reduce reactive oxygen species (ROS) production. Developed by Stealth BioTherapeutics, SS-31 has advanced through preclinical models of heart failure, ischemia-reperfusion injury, age-related muscle decline, kidney disease, and neurodegeneration β and into multiple clinical trials for conditions including Barth syndrome and primary mitochondrial myopathy.
In September 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to elamipretide (brand name Forzinity) as the first-ever treatment for Barth syndrome, marking a historic milestone as the first FDA-approved drug to directly target mitochondria. This article provides a comprehensive overview of SS-31‘s discovery, molecular structure, mechanism of action, published research findings, and current investigational applications in the context of mitochondrial and anti-aging peptide research.
What Is SS-31? Structure and Origin
Discovery and Development History
The story of SS-31 begins with a serendipitous discovery. In the early 2000s, researchers Dr. Hazel H. Szeto at Weill Cornell Medical College and Dr. Peter W. Schiller at the Clinical Research Institute of Montreal (IRCM) were investigating a family of small synthetic peptides originally designed to interact with opioid receptors. During this work, they observed that certain peptides in the series exhibited a remarkable and unexpected property: they rapidly concentrated within mitochondria at concentrations 1,000- to 5,000-fold higher than in the surrounding cytoplasm, independent of mitochondrial membrane potential (Szeto & Schiller, 2011).
This family of compounds became known as the Szeto-Schiller (SS) peptides. Among them, SS-31 β the 31st compound in the series β emerged as the lead candidate due to its potent mitochondria-targeting activity, favorable pharmacokinetic profile, and lack of significant opioid receptor activity at therapeutic concentrations. The peptide was subsequently developed under the names Elamipretide, Bendavia, and MTP-131 by Stealth BioTherapeutics, which advanced it into clinical-stage development (Szeto & Birk, 2014).
Amino Acid Sequence and Molecular Properties
SS-31 is a water-soluble, cell-permeable tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt denotes 2β²,6β²-dimethyltyrosine. Its molecular weight is approximately 640 Da, making it small enough for efficient cellular uptake.
The structural design of SS-31 incorporates several key features that enable its unique pharmacological activity:
Two positively charged residues (D-Arg and Lys): These cationic amino acids drive the electrostatic attraction of SS-31 toward the negatively charged inner mitochondrial membrane, which is enriched with the anionic phospholipid cardiolipin (Tung et al., 2025).
Two aromatic residues (Dmt and Phe): The hydrophobic aromatic rings facilitate membrane insertion and provide charge shielding through Ο-electron interactions, enabling SS-31 to penetrate cell membranes despite its net positive charge (Mitchell et al., 2020).
D-Arginine configuration: The use of the D-enantiomer of arginine confers resistance to enzymatic degradation, enhancing the peptide’s metabolic stability and bioavailability.
C-terminal amidation (-NH2): This modification prevents carboxypeptidase degradation and further stabilizes the peptide in biological environments.
The alternating aromatic-cationic motif (aromatic-cationic-aromatic-cationic) is a defining structural feature of the SS peptide family and is essential for mitochondrial targeting. This amphipathic design β with distinct hydrophobic and hydrophilic domains β allows SS-31 to interact simultaneously with the lipid bilayer and the aqueous mitochondrial matrix, positioning it precisely within the inner membrane where cardiolipin resides (Tung et al., 2025).
Importantly, SS-31‘s mitochondrial accumulation does not depend on the mitochondrial membrane potential (ΞΞ¨m), distinguishing it from triphenylphosphonium (TPP)-based mitochondrial carriers such as MitoQ. This feature is critical because dysfunctional mitochondria often exhibit depolarized membranes, meaning ΞΞ¨m-dependent agents lose their targeting ability precisely when they are needed most (Szeto & Birk, 2014). For researchers interested in related terminology and concepts, the Peptide Research Glossary provides a helpful reference.
Mechanism of Action
SS-31‘s therapeutic effects stem from its selective interaction with cardiolipin on the inner mitochondrial membrane. This interaction triggers a cascade of protective and restorative effects on mitochondrial structure and bioenergetics. Understanding this mechanism requires first appreciating the central role of cardiolipin in mitochondrial biology.
Cardiolipin: The Critical Target
Cardiolipin (CL) is a unique diphosphatidylglycerol lipid found almost exclusively in the inner mitochondrial membrane, where it comprises approximately 15-20% of total phospholipid content. Its distinctive structure β featuring four fatty acid chains attached to a glycerol backbone with two phosphate groups β enables it to perform several essential functions:
Cristae formation and maintenance: Cardiolipin promotes the curvature of the inner mitochondrial membrane, stabilizing the invaginated cristae folds that dramatically increase the surface area available for oxidative phosphorylation (Schlame & Ren, 2009).
ETC supercomplex assembly: Cardiolipin serves as a molecular βglueβ that holds electron transport chain complexes I, III, and IV together in higher-order supercomplexes (respirasomes), facilitating efficient electron transfer and minimizing electron leakage (Dudek et al., 2019).
Cytochrome c anchoring: Under normal conditions, cardiolipin tethers cytochrome c to the inner membrane, maintaining its electron-carrying function. During oxidative stress, cardiolipin oxidation causes cytochrome c release, triggering apoptosis (Houtkooper & Vaz, 2008).
ATP synthase function: Cardiolipin stabilizes ATP synthase (Complex V) oligomeric assemblies essential for ATP production.
When cardiolipin is damaged β through oxidative peroxidation, abnormal remodeling (as in Barth syndrome), or age-related degradation β mitochondrial cristae fragment, ETC efficiency collapses, ROS production escalates, ATP output plummets, and apoptotic pathways activate. This cascade of dysfunction is now understood to underlie a wide spectrum of diseases.
How SS-31 Interacts with Cardiolipin
SS-31 localizes to the inner mitochondrial membrane and binds cardiolipin through both electrostatic and hydrophobic interactions. The positively charged D-Arg and Lys residues form ionic contacts with cardiolipin’s negatively charged phosphate headgroups, while the aromatic Dmt and Phe residues insert into the hydrophobic lipid bilayer (Mitchell et al., 2020).
Research using model membranes has demonstrated that SS-31 modulates the surface electrostatics of cardiolipin-containing lipid bilayers, reducing the negative surface charge and altering the biophysical properties of the membrane in ways that stabilize cristae geometry (Mitchell et al., 2020). A landmark study published in Proceedings of the National Academy of Sciences mapped SS-31‘s mitochondrial protein interaction landscape, revealing that it interacts with multiple cardiolipin-binding proteins involved in both oxidative phosphorylation and fatty acid oxidation pathways (Campbell et al., 2020).
Downstream Protective Effects
The binding of SS-31 to cardiolipin produces several interconnected protective effects:
Cristae stabilization: By preventing cardiolipin peroxidation and maintaining membrane curvature, SS-31 preserves the structural integrity of mitochondrial cristae β the membrane folds essential for housing ETC complexes (Birk et al., 2013).
Enhanced electron transport and ATP production: SS-31 promotes the assembly and stability of ETC supercomplexes, facilitating more efficient electron transfer through complexes I, III, and IV. This reduces electron leakage and enhances coupling between oxygen consumption and ATP synthesis (Tung et al., 2025).
Reduced ROS generation: By improving ETC efficiency and minimizing electron leak (a primary source of mitochondrial superoxide), SS-31 significantly lowers mitochondrial ROS production. This breaks the vicious cycle in which ROS damage cardiolipin, which further impairs ETC function, which generates more ROS (Szeto & Birk, 2014).
Inhibition of mitochondrial permeability transition pore (mPTP) opening: Oxidative stress and calcium overload cause the mPTP to open during cellular injury (particularly ischemia-reperfusion), leading to mitochondrial swelling, depolarization, and cell death. SS-31 stabilizes ΞΞ¨m and reduces the triggers for mPTP opening, protecting against necrotic and apoptotic cell death (Tung et al., 2025).
Prevention of cytochrome c release: By stabilizing the cardiolipin-cytochrome c interaction, SS-31 prevents the detachment and release of cytochrome c into the cytoplasm, thereby inhibiting the intrinsic apoptotic cascade (Birk et al., 2013).
Anti-fibrotic effects: In preclinical models, chronic SS-31 administration has reduced tissue fibrosis by mitigating the oxidative stress and mitochondrial dysfunction that drive fibroblast activation and extracellular matrix deposition (Sabbah et al., 2016).
This multi-layered mechanism β operating at the intersection of membrane biophysics, bioenergetics, and cell survival signaling β distinguishes SS-31 from conventional antioxidants and positions it as a first-in-class mitochondrial therapeutic. For a deeper exploration of compounds that address age-related cellular decline, see our guide on anti-aging peptides in research.
Published Research Findings
SS-31 has been the subject of extensive preclinical and clinical investigation. Below is a summary of key published findings organized by research domain, supported by citations to peer-reviewed studies.
Cardiovascular Research and Heart Failure
Heart failure is characterized by progressive mitochondrial dysfunction in cardiomyocytes, with diminished ATP synthesis, elevated ROS, loss of cristae structure, and abnormal cardiolipin profiles. SS-31‘s ability to directly address these deficits has made cardiovascular research a primary area of investigation.
In a landmark preclinical study, Sabbah et al. demonstrated that chronic subcutaneous administration of elamipretide in dogs with experimentally induced advanced heart failure significantly improved left ventricular ejection fraction, stroke volume, and cardiac output while reducing left ventricular end-diastolic pressure and systemic vascular resistance. Importantly, these functional improvements were accompanied by normalization of ATP synthesis rates, reduced ROS formation, and reversal of cardiomyocyte hypertrophy and interstitial fibrosis (Sabbah et al., 2016).
Sabbah HN et al. βChronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.β Circulation: Heart Failure, 9(2), e002206, 2016.
A follow-up study by the same group showed that elamipretide also restored skeletal muscle mitochondrial function and normalized the type 1:type 2 muscle fiber ratio in heart failure models, suggesting potential benefits for the exercise intolerance that characterizes chronic heart failure (Sabbah et al., 2019).
Sabbah HN et al. βEffects of elamipretide on skeletal muscle in dogs with experimentally induced heart failure.β ESC Heart Failure, 6(2), 328-335, 2019.
In a first-in-human heart failure study, Daubert et al. conducted a randomized, placebo-controlled trial demonstrating that a single intravenous infusion of elamipretide significantly reduced left ventricular end-diastolic and end-systolic volumes in patients with heart failure with reduced ejection fraction (HFrEF) (Daubert et al., 2017).
Daubert MA et al. βNovel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.β Circulation: Heart Failure, 10(12), e004389, 2017.
The larger Phase 2 PROGRESS-HF trial subsequently evaluated four weeks of daily elamipretide in stable HFrEF. While the primary endpoint (reduction in LVESV) was not met, trends toward improved quality of life were observed, and investigators noted that longer treatment durations or assessment during exercise may be needed to capture the full benefit of mitochondrial restoration in this population (Butler et al., 2020).
Additional preclinical work demonstrated that SS-31 (under the name Bendavia) restored mitochondrial energy metabolism gene expression and suppressed cardiac fibrosis in the border zone of infarcted rat hearts, suggesting protective effects in the post-myocardial infarction setting (Shi et al., 2015).
Shi J et al. βBendavia restores mitochondrial energy metabolism gene expression and suppresses cardiac fibrosis in the border zone of the infarcted heart.β Life Sciences, 141, 170-178, 2015.
Barth Syndrome
Barth syndrome (BTHS), a rare X-linked genetic disorder caused by mutations in the Tafazzin (TAZ) gene, results in defective cardiolipin remodeling and severe mitochondrial dysfunction. Given SS-31‘s cardiolipin-targeting mechanism, BTHS represents a paradigmatic indication for this peptide.
The pivotal TAZPOWER clinical trial β a Phase 2/3 randomized, double-blind, placebo-controlled crossover study β evaluated daily subcutaneous elamipretide in patients with Barth syndrome. The trial demonstrated significant improvements in skeletal muscle strength and cardiac stroke volume after 48 weeks of treatment (Thompson et al., 2021).
Thompson WR et al. βA phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome.β Genetics in Medicine, 23(3), 471-478, 2021.
A subsequent 168-week open-label extension study confirmed sustained long-term efficacy and tolerability, with significant improvements from baseline in six-minute walk test distance, total fatigue scores, cardiac parameters (stroke volume, LVEDV, LVESV), and the monolysocardiolipin-to-cardiolipin (MLCL/CL) ratio β a direct biomarker of tafazzin dysfunction (Hornby et al., 2024).
Hornby B et al. βLong-term efficacy and safety of elamipretide in patients with Barth syndrome.β Genetics in Medicine, 26(5), 101097, 2024.
These results formed the basis for the FDA’s accelerated approval of Forzinity (elamipretide) in September 2025, making it the first drug approved to directly target mitochondria and the first approved treatment for Barth syndrome.
Preclinical research using a tafazzin-knockdown murine model further showed that SS-31 treatment restored mitochondrial cristae morphology and corrected defective mitophagy in cardiac tissue, providing mechanistic insight into how the peptide addresses BTHS pathology at the organelle level (Russo et al., 2024).
Russo S et al. βSS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome.β Scientific Reports, 14, 13655, 2024.
Aging and Skeletal Muscle Research
Age-related mitochondrial dysfunction β characterized by declining ETC efficiency, increased ROS, and reduced ATP output β contributes to sarcopenia, exercise intolerance, and multi-organ functional decline. SS-31 has shown remarkable promise in reversing these age-related deficits in preclinical models.
Siegel et al. demonstrated that just one hour of SS-31 treatment rapidly improved mitochondrial energetics and reversed age-related deficits in skeletal muscle performance in aged mice, with improvements in mitochondrial ATP production, reduced ROS emission, and enhanced muscle force generation (Siegel et al., 2013).
Siegel MP et al. βMitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.β Aging Cell, 12(5), 763-771, 2013.
Building on this work, Campbell et al. showed that eight weeks of SS-31 treatment restored redox homeostasis, improved mitochondrial quality, and increased exercise tolerance in aged mice β without increasing total mitochondrial content β suggesting that SS-31 improves the function of existing mitochondria rather than stimulating biogenesis (Campbell et al., 2019).
Campbell MD et al. βImproving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice.β Free Radical Biology and Medicine, 134, 268-281, 2019.
A study published in eLife demonstrated that eight weeks of SS-31 treatment in old mice substantially reversed age-related cardiac diastolic dysfunction, proteome remodeling, and mitochondrial proton leak β providing evidence that late-life restoration of mitochondrial function can reverse established cardiac aging (Dai et al., 2020).
Dai DF et al. βLate-life restoration of mitochondrial function reverses cardiac dysfunction in old mice.β eLife, 9, e55513, 2020.
For researchers interested in other peptides studied for age-related decline, MOTS-c is another mitochondria-derived peptide with complementary mechanisms, while Epithalon is investigated in telomere-related aging research.
Kidney Injury and Renal Protection
The kidneys are among the most metabolically active organs in the body, with renal tubular cells relying heavily on mitochondrial oxidative phosphorylation. SS-31 has been extensively studied in models of acute kidney injury (AKI), ischemia-reperfusion injury, and chronic kidney disease.
Birk et al. demonstrated that SS-31 re-energized ischemic mitochondria by interacting with cardiolipin, restoring ATP levels and mitochondrial membrane potential in renal tissue following ischemia-reperfusion injury. This study was instrumental in establishing that SS-31‘s primary mechanism involves cardiolipin binding rather than direct ROS scavenging (Birk et al., 2013).
Birk AV et al. βThe mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.β Journal of the American Society of Nephrology, 24(8), 1250-1261, 2013.
In aged mice, SS-31 treatment improved glomerular mitochondrial morphology, reduced age-related glomerulosclerosis, and decreased expression of the oxidative stress enzyme Nox4 and cellular senescence markers p16 and p21 β demonstrating renoprotective effects against age-related kidney decline (Szeto et al., 2017).
Szeto HH et al. βThe mitochondrial-targeted peptide, SS-31, improves glomerular architecture in aging.β Kidney International, 91(2), 460-471, 2017.
A Phase 2a clinical trial evaluated adjunctive elamipretide during percutaneous transluminal renal artery stenting (PTRA) in patients with atherosclerotic renal artery stenosis. Elamipretide administration was associated with attenuated post-procedural hypoxia, increased renal blood flow, and improved glomerular filtration rate at three-month follow-up (Saad et al., 2017).
Saad A et al. βPhase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.β Circulation: Cardiovascular Interventions, 10(9), e005487, 2017.
Neurodegenerative Disease Research
Mitochondrial dysfunction and oxidative stress are implicated in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions. SS-31 has demonstrated neuroprotective potential across multiple preclinical models.
In Alzheimer’s disease research, Manczak et al. showed that SS-31 protected mouse neuroblastoma cells and Alzheimer’s disease model neurons against amyloid-beta (AΞ²) toxicity by preserving mitochondrial function, reducing oxidative stress, and increasing neurite outgrowth (Manczak et al., 2010).
Manczak M et al. βMitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer’s disease neurons.β Journal of Alzheimer’s Disease, 20(S2), S609-S631, 2010.
In Parkinson’s disease models, Yang et al. demonstrated that SS-31 provided dose-dependent protection of dopaminergic neurons against MPTP-induced neurotoxicity, preserving mitochondrial function and reducing oxidative damage in the substantia nigra (Yang et al., 2009).
Yang L et al. βMitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.β Antioxidants & Redox Signaling, 11(9), 2095-2104, 2009.
A comprehensive review by Nhu et al. further highlighted SS-31‘s potential to prevent the progressive development of neurodegenerative diseases by enhancing mitochondrial respiration, biogenesis, and dynamics while reducing neuroinflammation (Nhu et al., 2021).
Nhu NT et al. βNeuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration.β Frontiers in Integrative Neuroscience, 15, 747901, 2021.
Researchers exploring neuroprotective peptides may also find relevant information in our GHK-Cu research guide, as GHK-Cu has been investigated for its own neuroprotective and tissue-remodeling properties.
Research Applications
SS-31 is currently being investigated across a wide spectrum of research applications related to mitochondrial dysfunction. The following areas represent active and emerging domains of scientific inquiry.
Primary Mitochondrial Diseases
Beyond Barth syndrome, SS-31 has been evaluated in primary mitochondrial myopathies (PMM) β a group of genetic disorders affecting oxidative phosphorylation. The Phase 3 MMPOWER-3 trial evaluated elamipretide in genetically confirmed PMM. While the trial did not meet its primary endpoint of improved six-minute walk test distance in the overall population, a subgroup of participants with nuclear DNA (nDNA) maintenance-related defects showed meaningful improvements, leading to the design of the follow-up NuPOWER trial targeting this specific genetic subtype (Karaa et al., 2020).
Age-Related Macular Degeneration
The ReCLAIM trials (Phase 2) investigated elamipretide in patients with dry age-related macular degeneration (AMD). Although primary endpoints of visual acuity improvement and geographic atrophy reduction were not met, elamipretide slowed the degradation of the ellipsoid zone (EZ) β a mitochondria-rich layer of photoreceptors β suggesting potential for preserving photoreceptor function and slowing AMD progression.
Ischemia-Reperfusion Injury
SS-31 continues to be investigated as a protective agent against ischemia-reperfusion injury across multiple organs. In cardiac research, the EMBRACE-STEMI trial evaluated elamipretide in first-time anterior ST-elevation myocardial infarction patients. While the primary endpoint of infarct size reduction was not achieved, a reduced incidence of new-onset heart failure within 24 hours post-PCI was observed in the elamipretide group. Preclinical studies have further demonstrated that elamipretide mitigates fragmentation of cristae networks following cardiac ischemia-reperfusion in rat models (Allen et al., 2020).
Allen ME et al. βThe cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats.β Communications Biology, 3, 389, 2020.
Doxorubicin-Induced Cardiotoxicity
Multiple preclinical investigations have explored SS-31 as a cardioprotective adjunct during doxorubicin chemotherapy. Studies demonstrate that SS-31 reduces ROS production, stabilizes mitochondrial membrane potential, and attenuates myocardial apoptosis and fibrosis following doxorubicin administration (Zhang et al., 2019; Yeh et al., 2021).
Metabolic and Diabetic Complications
Research has explored SS-31‘s protective effects in metabolic disorders, including high-fat diet-induced kidney injury and diabetic nephropathy. Szeto et al. demonstrated that mitochondrial protection with SS-31 prevented high-fat diet-induced glomerulopathy and proximal tubular injury in murine models (Szeto et al., 2016).
Szeto HH et al. βProtection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury.β Kidney International, 90(5), 997-1011, 2016.
These diverse research applications reflect the fundamental role of mitochondrial dysfunction in disease pathology and the broad potential of cardiolipin-targeted interventions. Investigators studying mitochondrial health may also be interested in NAD+, which supports mitochondrial function through a complementary bioenergetic pathway, and MOTS-c, a mitochondrial-derived peptide being studied for metabolic regulation.
Comparison with Related Compounds
SS-31 occupies a unique niche among mitochondria-targeted compounds and peptide therapeutics. Understanding how it compares to related agents provides important context for research design.
SS-31 vs. MitoQ and Other TPP-Conjugated Antioxidants
MitoQ (mitoquinone) and similar triphenylphosphonium (TPP)-conjugated antioxidants rely on the mitochondrial membrane potential (ΞΞ¨m) for mitochondrial accumulation. This Nernstian distribution means these compounds concentrate effectively in healthy, polarized mitochondria but lose their targeting ability in dysfunctional, depolarized mitochondria. SS-31, by contrast, accumulates in mitochondria independently of ΞΞ¨m, making it effective precisely in the disease states where mitochondrial targeting is most needed (Szeto & Birk, 2014). Furthermore, SS-31 does not merely scavenge ROS; it addresses the root cause of excess ROS production by stabilizing ETC supercomplex architecture through cardiolipin interactions.
SS-31 vs. MOTS-c
MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome. Unlike SS-31, which is a synthetic exogenous compound that targets the inner mitochondrial membrane, MOTS-c is an endogenous signaling peptide that translocates to the nucleus to regulate metabolic gene expression, particularly under cellular stress. While both compounds improve mitochondrial function, they operate through fundamentally different mechanisms: SS-31 works at the structural/bioenergetic level of the inner membrane, while MOTS-c functions as a retrograde signaling molecule. Research into MOTS-c has primarily focused on metabolic regulation, exercise mimetic effects, and insulin sensitivity.
SS-31 vs. NAD+ Precursors
NAD+ and its precursors (NMN, NR) support mitochondrial function by maintaining the NAD+/NADH ratio critical for ETC complex I activity and sirtuin-mediated mitochondrial quality control. SS-31 and NAD+ precursors address mitochondrial dysfunction through complementary but distinct pathways: SS-31 targets structural integrity at the membrane level, while NAD+ supports the substrate-level requirements of oxidative metabolism. Some researchers have explored combinatorial approaches leveraging both mechanisms.
SS-31 vs. Epithalon
Epithalon is a synthetic tetrapeptide studied for its effects on telomerase activation and telomere maintenance. While both SS-31 and Epithalon are investigated in aging research contexts, their mechanisms are entirely different: SS-31 targets mitochondrial bioenergetics, while Epithalon addresses chromosomal stability. Together with compounds like GHK-Cu, which is studied for tissue remodeling and gene expression modulation, and BPC-157, which has been researched for cytoprotective signaling, these peptides represent complementary approaches to age-related biological decline.
Frequently Asked Questions
What is SS-31 (Elamipretide)?
SS-31, also known as Elamipretide, Bendavia, or MTP-131, is a synthetic mitochondria-targeted tetrapeptide with the amino acid sequence D-Arg-Dmt-Lys-Phe-NH2. It selectively accumulates in the inner mitochondrial membrane, where it binds the phospholipid cardiolipin to stabilize mitochondrial cristae structure, enhance electron transport chain efficiency, increase ATP production, and reduce mitochondrial reactive oxygen species (ROS) generation. It was co-discovered by Dr. Hazel Szeto and Dr. Peter Schiller and is being developed by Stealth BioTherapeutics.
How does SS-31 work in research?
In research models, SS-31 concentrates at the inner mitochondrial membrane and binds cardiolipin through electrostatic and hydrophobic interactions. This binding stabilizes the arrangement of electron transport chain supercomplexes, reduces electron leakage that generates harmful ROS, maintains mitochondrial membrane potential, inhibits opening of the mitochondrial permeability transition pore (mPTP), and prevents cytochrome c release that triggers apoptosis. Published studies have demonstrated these effects across cardiac, renal, neuronal, and skeletal muscle tissues.
What conditions has SS-31 been studied for?
SS-31 has been investigated in preclinical and clinical studies for a range of conditions involving mitochondrial dysfunction, including heart failure (PROGRESS-HF trial), Barth syndrome (TAZPOWER trial, leading to FDA approval of Forzinity in 2025), primary mitochondrial myopathy (MMPOWER-3 trial), ischemia-reperfusion injury (EMBRACE-STEMI trial), atherosclerotic renal artery stenosis, dry age-related macular degeneration (ReCLAIM trials), Alzheimer’s disease, Parkinson’s disease, doxorubicin cardiotoxicity, diabetic nephropathy, and age-related skeletal muscle decline.
What makes SS-31 different from other antioxidants?
Unlike conventional antioxidants (such as vitamin C or vitamin E) that operate in the cytoplasm or plasma and scavenge free radicals after they are produced, SS-31 targets the source of ROS production β the mitochondrial electron transport chain β by stabilizing the cardiolipin-dependent architecture of ETC supercomplexes. Additionally, unlike TPP-conjugated mitochondrial antioxidants (e.g., MitoQ), SS-31 does not depend on mitochondrial membrane potential for its accumulation, allowing it to target dysfunctional, depolarized mitochondria that other agents cannot reach.
Has SS-31 received regulatory approval?
Yes. In September 2025, the U.S. FDA granted accelerated approval to elamipretide under the brand name Forzinity for the treatment of Barth syndrome in patients weighing at least 30 kg. This marked the first FDA-approved drug to directly target mitochondria and the first approved treatment for Barth syndrome. The approval was based on demonstrated improvements in skeletal muscle strength, with a confirmatory post-approval trial required.
What is the safety profile observed in research?
Across multiple clinical trials, elamipretide has demonstrated a generally favorable tolerability profile. The most commonly reported side effects were mild-to-moderate injection site reactions (pain, redness, swelling). Less common adverse events included headache, dizziness, nausea, and fatigue. In the 168-week open-label TAZPOWER extension, no clinically significant changes in vital signs, laboratory values, or ECG parameters were observed (Hornby et al., 2024; Tung et al., 2025).
How does SS-31 compare to other peptides studied for aging?
SS-31 addresses aging at the mitochondrial bioenergetic level by restoring ETC efficiency and reducing oxidative damage to mitochondrial components. Other peptides studied in aging research include MOTS-c (mitochondrial-derived metabolic signaling), Epithalon (telomerase activation), GHK-Cu (gene expression modulation and tissue remodeling), and NAD+ (bioenergetic cofactor supplementation). These compounds target different aspects of the aging process and represent complementary research approaches. For a broader overview, see our guide to anti-aging peptides in research.
Conclusion
SS-31 (Elamipretide) represents a landmark advance in mitochondrial therapeutics. By selectively binding cardiolipin at the inner mitochondrial membrane, this tetrapeptide addresses mitochondrial dysfunction at its structural and bioenergetic root β stabilizing cristae architecture, enhancing ETC supercomplex function, boosting ATP production, and reducing the oxidative stress that drives disease progression across organ systems.
The breadth of published research β spanning heart failure, Barth syndrome, aging, kidney injury, neurodegeneration, and beyond β underscores the fundamental importance of mitochondrial health in human biology and the potential of targeted interventions to restore it. The FDA’s 2025 accelerated approval of Forzinity for Barth syndrome marks a historic milestone, validating decades of research into mitochondria-targeted peptide therapeutics and opening the door for future applications in conditions ranging from primary mitochondrial diseases to age-related functional decline.
As the scientific community continues to elucidate the role of mitochondrial dysfunction in disease, SS-31 and related mitochondria-targeted compounds are poised to remain at the forefront of translational research. Researchers interested in exploring peptides that address cellular health, mitochondrial function, and age-related decline can explore Iron Peak Peptides’ full catalog of research-grade compounds including NAD+, MOTS-c, Epithalon, and GHK-Cu.
Research Disclaimer
This article is intended for educational and informational purposes only. All compounds mentioned are for laboratory research use only and are not intended for human consumption. Always consult applicable regulations and institutional guidelines before conducting research with any compounds.
References
Allen ME et al. βThe cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats.β Communications Biology, 3, 389, 2020.
Birk AV et al. βThe mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.β Journal of the American Society of Nephrology, 24(8), 1250-1261, 2013.
Campbell MD et al. βImproving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice.β Free Radical Biology and Medicine, 134, 268-281, 2019.
Campbell MD et al. βMitochondrial protein interaction landscape of SS-31.β Proceedings of the National Academy of Sciences, 117(26), 15363-15373, 2020.
Dai DF et al. βLate-life restoration of mitochondrial function reverses cardiac dysfunction in old mice.β eLife, 9, e55513, 2020.
Daubert MA et al. βNovel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.β Circulation: Heart Failure, 10(12), e004389, 2017.
Hornby B et al. βLong-term efficacy and safety of elamipretide in patients with Barth syndrome.β Genetics in Medicine, 26(5), 101097, 2024.
Manczak M et al. βMitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer’s disease neurons.β Journal of Alzheimer’s Disease, 20(S2), S609-S631, 2010.
Mitchell W et al. βThe mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action.β Journal of Biological Chemistry, 295(21), 7452-7469, 2020.
Nhu NT et al. βNeuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration.β Frontiers in Integrative Neuroscience, 15, 747901, 2021.
Russo S et al. βSS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome.β Scientific Reports, 14, 13655, 2024.
Saad A et al. βPhase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.β Circulation: Cardiovascular Interventions, 10(9), e005487, 2017.
Sabbah HN et al. βChronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.β Circulation: Heart Failure, 9(2), e002206, 2016.
Sabbah HN et al. βEffects of elamipretide on skeletal muscle in dogs with experimentally induced heart failure.β ESC Heart Failure, 6(2), 328-335, 2019.
Shi J et al. βBendavia restores mitochondrial energy metabolism gene expression and suppresses cardiac fibrosis in the border zone of the infarcted heart.β Life Sciences, 141, 170-178, 2015.
Siegel MP et al. βMitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.β Aging Cell, 12(5), 763-771, 2013.
Szeto HH & Birk AV. βSerendipity and the discovery of novel compounds that restore mitochondrial plasticity.β Clinical Pharmacology & Therapeutics, 96(6), 672-683, 2014.
Szeto HH & Schiller PW. βNovel therapies targeting inner mitochondrial membrane β From discovery to clinical development.β Pharmaceutical Research, 28(11), 2669-2679, 2011.
Szeto HH et al. βProtection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury.β Kidney International, 90(5), 997-1011, 2016.
Szeto HH et al. βThe mitochondrial-targeted peptide, SS-31, improves glomerular architecture in aging.β Kidney International, 91(2), 460-471, 2017.
Thompson WR et al. βA phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome.β Genetics in Medicine, 23(3), 471-478, 2021.
Tung C et al. βElamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.β International Journal of Molecular Sciences, 26(3), 944, 2025.
Yang L et al. βMitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.β Antioxidants & Redox Signaling, 11(9), 2095-2104, 2009.
🔬 Explore Research Peptides
- GHRP-6 10mg — $39.00
- Ipamorelin 10mg — $52.99
- TB-500 10mg — $69.99
- Clomid 50mg β 100 Tablets — $69.00
